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The difference between men and women is clear even just by looking at an electrocardiogram: females present higher resting heart rate, a
shorter QRS complex length and greater corrected QT interval. The development of these differences from pubertal age onward suggests
that sexual hormones play a key role, although their effect is far from being completely understood. Different incidences between sexes
have been reported for many arrhythmias, both ventricular and supraventricular, and also for sudden cardiac death. Moreover, arrhyth-
mias are an important issue during pregnancy, both for diagnosis and treatment. Interestingly, cardiovascular structural and electrophysio-
logical remodelling promoted by exercise training enhances this ‘gender effect’. Despite all these relevant issues, we lack gender specific
recommendations in the current guidelines for electrical therapies for heart rhythm disorders and heart failure. Even more, we continue
to see that fewer women are included in clinical trials and are less referred than men for these treatments.
...................................................................................................................................................................................................
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Introduction
The importance of sex differences in both physiology and pathology
dates to the beginning of early research and medicine. Focusing on
electrophysiology, at the beginning of the 20th century, Bazett
observed that women have a higher resting heart rate than men.1
Awareness of the importance of gender influence is growing, but
many current trials on several pharmacological and non-
pharmacological treatments still lack adequate representation of the
female population and sex-specific analysis, although their findings are
often extended to women in general. In this review, we aim to point
out the main gender-related differences concerning the electrophy-
siological properties of the heart, arrhythmia epidemiology and
access to therapies.
Gender and electrical physiology
of the heart
Several electrophysiological properties were found to be significantly
affected by sex.2–4 In particular, women present:
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• enhanced sinoatrial node automaticity, independent of the influ-
ence of the autonomic system, with shorter sinus cycle length and
shorter sinus recovery time, especially during pregnancy5,6;
• enhanced atrio-ventricular node function: with shorter AH interval
and atrio-ventricular node effective refractory period7;
• faster infra-hisian conduction: with shorter HV interval6,7;
• longer ventricular action potential duration: occurring in the post-
pubertal phase.4
The standard 12-lead ECG reflects most of these differences, as
shown in Figure 1. Women show a 3–5 beats/min higher heart rate at
rest.1,8 This appears to be related to sexual hormone effects, auto-
nomic nervous system influences and the already mentioned intrinsic
properties of the sinus node.5,9 Available data suggest that P wave
length is significantly shorter in women (female 118 ± 9 ms, male
122 ± 8 ms)10 and, as a result of reduced AH and HV intervals, women
also show a shorter PR interval.6 Notably, the two most important
ECG findings are the shorter QRS duration and the more prolonged
corrected QT (QTc) interval in women.2–4,11 In prepubertal age, QRS
duration lengthens gradually from birth without significant differences
between the sexes,12 but starting from adolescence QRS becomes
wider in males (90 ± 12 ms in males, 68 ± 13 ms in females).6 Lower
cardiac mass has been suggested as an explanation, but this difference
persists even after correction for body weight and cardiac mass.13,14
It has been clearly established that the QTc interval is longer in
women,4,15,16 and this is clinically relevant because a higher QTc inter-
val duration is associated with increased arrhythmic risk, in particular
of Torsade de Pointes.17 Also this difference becomes more evident
after puberty.18 After menopause, the QTc difference between the
sexes is negligible.18 This suggests that sexual hormones play an impor-
tant role in gender related difference in heart electrical physiology with
a particularly evident effect in myocardial repolarization. Indeed, Burke
et al.19 showed a different length of QTc interval during the menstrual
cycle (shorter QTc interval occurring in the progesterone-dependent
luteal phase), only present after double autonomic blockade.
However, in the absence of drug-induced autonomic nervous system
block, there is no clear evidence regarding QTc interval variation dur-
ing menstrual cycle.20,21 Cardiomyocytes possess cell receptors for
the three main sex-steroid hormones (oestrogens, progesterone, and
testosterone),22 all of which seem to affect myocardial repolarization:
endogenous testosterone and progesterone shorten the action poten-
tial, while oestrogens were shown to increase QTc interval duration in
animal studies.23–26 In particular, estradiol’s effect on QTc appears to
be mediated by down-regulation of the expression of potassium chan-
nel currents, such as the slowly activating delayed rectifier current,
which play a role in myocardial repolarization.24 However, these find-
ings have not been replicated in human studies.26,27 Testosterone-
induced QTc interval shortage in males after puberty also contributes
to explain QTc interval duration difference between the sexes.14,26,28
Gender and epidemiology of
arrhythmias
Evaluation of epidemiological differences of clinical arrhythmias
between females and males is a hard task since referral for treatment
of these conditions is affected by several factors besides disease
occurrence (as discussed below). However, despite the mentioned
limitations, available data highlight a different prevalence among
females (vs. males) for several arrhythmias (Figure 2).2,13,29,30 In the
field of supraventricular tachyarrhythmias, women have a higher
prevalence of AV nodal re-entrant tachycardias (AVNRT), and focal
automatic tachycardias, while accessory-pathways (both manifest and
concealed), with/without atrioventricular re-entrant tachycardia
(AVRT) have a greater prevalence in males. Notably, the occurrence
of specific episodes of supraventricular arrhythmia may vary with the
menstrual cycle, being more frequent in the luteal phase.
Figure 1 Different gender-related characteristics of cardiac elec-
trophysiology as reflected by surface 12-lead ECG. E.R., early
repolarisation.
Figure 2 Epidemiological differences in the prevalence of princi-
pal arrhythmias between female (F) and male (M) patients. AF, atrial
fibrillation; AVNRT, atrio-ventricular node reentrant tachycardia;
AVRT, atrio-ventricular reentrant tachycardia; AT, atrial tachycar-
dia; LQTS, Long QT syndrome; RVOT, right ventricular outflow
tachycardia; SCD, sudden cardiac death; SND, sinus node disease;
VF, ventricular fibrillation; VT, ventricular tachycardia.
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Although the reason for this correlation has not been established,
hormonal and autonomic factors seem to be involved.31,32 Similar
findings have also been reported for ventricular premature com-
plexes, whose frequency is lower in the ovulation period.33 Males
have a higher prevalence of flutter and atrial fibrillation (AF) at all
ages (about 1.5-fold higher risk, Figure 2), but since women present
an overall greater longevity, doubling the number of living men over
75 years, the prevalence of AF in women is greater than that of men
at older age and on the whole is almost equal (53% of all patients
with AF according to data from the Mayo Clinic).34,35
Some gender-related differences have been reported regarding the
prevalence of various idiopathic VTs, with the right ventricular outflow
tract VT form more prevalent in women, the left ventricular septal VT
form more frequent in men and the left ventricular outflow tract VT
form equally distributed.36 However, the most important findings
regard incidence of sudden cardiac death and long-QT syndrome. In
general, females present a lower incidence of sudden death both at
younger and older age.37 This can only partially be explained by a
lower incidence of structural heart diseases in female subjects: in car-
diac arrest survivors and autopsy series, coronary artery disease was
found in 45–50% of women vs. 80–90% of men, and at post-mortem
evaluation women more frequently presented a structurally normal
heart.37–39 On the other hand, a higher prevalence of female subjects
has been reported in long-QT syndrome, both in genetically deter-
mined and acquired (drug induced) forms.16,30 Notably, in inherited
long-QT syndrome40 the occurrence of symptomatic events is higher
in boys before puberty, but higher in females later. An evident influ-
ence of gender has been reported for Brugada syndrome too: the inci-
dence of typical ECG pattern is more frequent in males (with an 8:1
predominance), while risk of sudden cardiac death or clinically relevant
arrhythmia was more than 3 times higher in men than in women.41,42
Regarding bradyarrhythmias, in a large, real-life retrospective study
women were found to be more likely to undergo pacemaker implan-
tation for sick sinus syndrome than males, while atrioventricular
blocks represent a more important indication in men.43
Pregnancy and arrhythmias
The most important ECG changes described during pregnancy are an
increase of heart rate with reduced heart rate variability and a signifi-
cant QTc interval lengthening.44 Pregnancy is a particular condition
for arrhythmias too: about 1–4% of pregnant women without struc-
tural heart disease will present arrhythmias during pregnancy.
However, only a few of these will need specific treatment. While his-
tory of previous arrhythmias seems to be the most important predic-
tor of arrhythmia recurrence during pregnancy, there are conflicting
data regarding the evolution of the arrhythmic pattern in these
patients.45–47 In some cases, especially in subjects with Wolff–
Parkinson–White syndrome, an increase in arrhythmic burden has
been reported. The mechanism underlying this arrhythmic burden
increase is not fully explained, but likely it is the result of the haemody-
namic, hormonal and increased sympathetic tone that occurs in preg-
nancy.48 In these subjects, the first step is to exclude any transient
cause, especially electrolyte imbalances and thyroid dysfunction
(hyperthyroidism may occur in 5–15% of women peri-partum and in
4–8% post-partum). Notably, several factors contribute to the
reported symptoms and in up to 90% of the subjects there is no asso-
ciation between symptoms and Holter/ECG findings.49 Available data
suggest that ventricular arrhythmias are unusual during pregnancy in
patients without pre-existing heart disease.2,46 Conversely, patients
with known long QT syndrome (Type 1 and 2) present an increased
likelihood of arrhythmic event in the post-partum period.44 The num-
ber of pregnant women with congenital heart disease (CHD) is con-
stantly rising, and this group is at particular high risk of arrhythmias
during pregnancy.50 Intrinsic conduction abnormalities, volume over-
load, persistence of operative scar and impaired autonomic nervous
system are the main contributors to the development of heart rhythm
disorders.51 The risk of clinically relevant arrhythmias for women with
CHD was reported to be about 4.5% in completed pregnancy, but it
is strictly related to the underlying CHD, being the highest for atrio-
ventricular septal defect, post-operative Fontan and corrected tetral-
ogy of Fallot and complete transposition of the great arteries.52 For
patients with CHD, pre-pregnancy counselling is recommended and,
in some cases, pregnancy should be discouraged.53,54
Gender and cardiovascular
response to exercise training
Constant physical activity leads to multiple adaptations, in particular
involving the heart and autonomic nervous system, which may become
manifest on the ECG. Training-related ECG modifications in athletes
include sinus bradycardia and new atrioventricular blocks (mainly first
degree and Mobitz 1) and junctional rhythm, early repolarization pat-
tern (ERP), positivity to voltage criteria for left ventricle hypertrophy
and right bundle branch block.55 These changes are less expressed in
female athletes: in particular, those concerning QRS criteria for left
ventricle hypertrophy and ERP.55–57 A lower prevalence of partial right
bundle branch block and sinus bradycardia has also been reported, but
there is conflicting evidence of this finding.56,57 No significant difference
has been described for antrioventricular blocks and junctional
rhythm.56 Interestingly, not only is ERP less frequent in female athletes,
but it also seems to be differently represented on the 12-lead ECG.
Wafsy et al.57 reported that the higher prevalence of ERP in males was
mainly due to an anterior distribution of the ERP on ECG leads, while
Junttila et al.58 reported a significant higher prevalence of ERP in the
inferior leads in males. These findings are relevant when considered in
light of the association between presence of ERP in the inferior leads
and incidence of sudden cardiac death in the general population59 and
the increased risk of sudden cardiac death in age-matched athletes,60
especially males.61 This is a relevant topic for future studies.
The described differences in ECG morphology among female ath-
letes are probably due to a different expression of heart remodelling
in response to exercise training. Male athletes present a more pro-
nounced concentric left ventricular hypertrophy and atrial remodel-
ling62 coupled with a longer signal-averaged P-wave duration. These
findings may represent the substrate for a higher prevalence of atrial
fibrillation in male athletes.63 However, we lack definite data confirm-
ing this hypothesis. A recent metanalysis64 reported that only studies
enrolling exclusively male subjects showed a higher incidence of AF
in trained athletes, a finding not confirmed in mixed sex reports.
However, this evidence is limited by the lack of significance when
directly comparing incidence of AF among female and male athletes
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in studies enrolling mixed sex populations. Notably, a recent report
from the EORP-AF Registry showed that physical activity seems not
to be associated with arrhythmia progression in patients with a his-
tory of AF.65
Effects of gender on access to
electrical therapies
Several reports66–90 highlighted a different referral for electrical
therapies in male and female subjects (Tables 1 and 2), and this behav-
iour is also observed in common clinical practice and clinical research.
Dhruva et al.91 performed a systematic review of 78 high-risk devices,
which received premarket approval from the FDA between 2000
and 2007, and showed that 28% of the studies did not report any
data on the gender of study participants, while in the remaining cases
women, on average, represented 33% of the device recipients. Forty-
one percent of the studies presented a specific comment/analysis on
sex discrepancies and about one fourth of these analyses showed
some sex-related differences in terms of safety/efficacy.
An analysis of the major trials focused on implantable cardioverter
defibrillator (ICD) shows a limited prevalence of females among the
enrolled subjects (about 20–30%, Table 1),66–72,74–77,80–82,86 that are
difficult to explain with mere epidemiological factors. The same
occurred for trials involving ablation of supraventricular arrhythmias
(Table 2).73,78,79,83–85,87 Similar findings are confirmed in reports from
high volume centres and in multi-centre registries. Treatment of AF is
a paradigm: women with AF have more comorbidities (especially
heart failure with preserved systolic function) and a lower quality of
life, but they are more frequently treated with a conservative
approach, mainly based on a rate control strategy. This happens
despite the fact that catheter ablation could represent an attractive
alternative in appropriately selected patients.92–96 In addition, women
are referred for AF ablation later in the course of the disease (e.g.
after a longer history of AF, when left atrium dimensions are larger
than those observed in men), usually after several failed attempts
with antiarrhythmic drugs. They are also older and with more co-
morbidities (e.g. valvular heart disease, rheumatic disease and hyper-
tension).93,97,98 Similar data were reported for AVNRT/AVRT abla-
tion, with female candidates referred after a longer use of
antiarrhythmic drugs (30% vs. 8%; P = 0.022) than males.99 Notably,
women have a twice higher probability than men of undergoing mis-
diagnosis between SVT and panic disorder,100 which could contribute
to a delay in the diagnosis of arrhythmias.
Moving on to electrical therapies applied in patients with left ventric-
ular dysfunction and heart failure, an imbalance in referral of female vs.
male patients is confirmed. Despite the higher prevalence of ischaemic
heart disease in male subjects, hospitalization for heart failure is no less
frequent in female patients,101 reflecting a higher prevalence of the dis-
ease especially at advanced ages. However, females are under-referred
for cardiac resynchronization therapy (CRT), as reported by several
authors,102–104 with the implantation rate being 1–5 for all age
classes.105,106 This gap is also present in the chance of receiving an
ICD, and is not limited to acquired cardiomyopathies (with the possi-
ble driver of the prevalence of ischaemic heart disease) but also for
inherited disease, both in primary and secondary prevention.107–110
These data were confirmed by a recently published large multi-centre
French registry (female prevalence 15.1%),111 and the Defibrillator
Implantation in Patients with Nonischemic Systolic Heart(DANISH)
trial (female prevalence 27–28%).112 Noteworthy, a post hoc analysis
of the Antiarrhythmics vs. Implantable Defibrillators (AVID) trial
showed a similarly low prevalence of the female sex in both screened
and enrolled patients for ICD implantation for secondary prevention
(25% vs. 22% P = 0.313).113 This suggests that female underrepresenta-
tion in ICD trials may not be due to a ‘study-driven’ selection bias. The
main reasons may belong to a different clinical profile (leading to exclu-
sion by enrolment criteria) or to a general under referral of women
for non-pharmacological therapies.
Possible explanations for the under-referral of female patients for
device therapy are
(1) longer time to diagnosis;
(2) subject preference for a non-invasive approach;
(3) medical concerns regarding X-ray-related complications;
(4) medical concerns regarding higher chance of procedural
complications;
(5) tendency to a less intensive pattern of resource utilization;
(6) higher ratio of heart failure with preserved left ventricular ejection
fraction, that may reduce indications for cardiac implantable electri-
cal devices implantation compared to men.114
However, this phenomenon has not yet been fully defined.
Notably, when looking at the appropriateness of indication, no differ-
ence between the sexes has been reported for ICD or CRT
implantation.54,115
Conclusions
Several aspects of cardiac electrophysiology are influenced by gender.
At the 12-lead ECG, females present a higher heart rate at rest,
shorter QRS, and longer QTc interval. Incidence of specific arrhyth-
mias and sudden death is also affected by gender, with AVNRT and
focal tachycardias occurring more frequently in females while AVRT
and atrial fibrillation/flutter and sudden cardiac death are more fre-
quently reported in male subjects. These characteristics are more
pronounced in athletes also due to a greater cardiovascular remodel-
ling in male subject in response to exercise training. In addition, preg-
nancy is a particular setting for the occurrence of arrhythmias both
for diagnosis and treatment. Supraventricular arrhythmias are fre-
quently expressed, while ventricular events are rare. Notably,
women with CHD represent a population at higher risk of severe
arrhythmic complications. We need further investigations to better
define the mechanisms underlying these gender-related differences:
physical, autonomic and hormonal effects are certainly involved, but
their role still needs to be fully characterized. More importantly,
females are seldom represented in clinical research (i.e. one-fifth to
one-fourth of the enrolled patients) and are infrequently referred for
electrical treatments for arrhythmias and heart failure in clinical prac-
tice. Among the various explanations, a difference in epidemiology
and in clinical response is far from being the most important.
Conflict of interest: none declared.
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